Back to News
Market Impact: 0.05
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Source: globenewswire.com
Healthcare & BiotechManagement & Governance
Tempest Therapeutics, a clinical-stage developer of in vivo CAR-T therapies for cancer and autoimmune disease, issued an announcement referencing Matt Angel, Ph.D. The provided article text is incomplete and does not disclose the nature of the announcement, financial terms, clinical data, or expected business impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
TPST0.10
More News
- Apple's $2000+ iPhone, Oil Gain Stokes Inflation Fear | Bloomberg Businessweek Daily 9/8/2026
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026
- History Says September Is the Worst Month for Stocks. Here’s 1 Stock With a Major Catalyst This Month to Buy and Hold